![Jay Kranzler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jay Kranzler
Voorzitter bij AVENUE THERAPEUTICS, INC.
Vermogen: 409 $ op 31-05-2024
Actieve functies van Jay Kranzler
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AVENUE THERAPEUTICS, INC. | Independent Dir/Board Member | 01-02-2017 | - |
Voorzitter | 07-03-2023 | - | |
Directeur/Bestuurslid | 01-02-2017 | 07-03-2023 | |
Regenovation, Inc.
![]() Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
ImmunoBrain Checkpoint Ltd.
![]() ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
Pastorus, Inc.
![]() Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | Directeur/Bestuurslid | - | - |
Hoofd Techniek/Wetenschap/O&O | - | - | |
Baergic Bio, Inc.
![]() Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Directeur/Bestuurslid | - | - |
Loopbaan van Jay Kranzler
Eerdere bekende functies van Jay Kranzler
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Cypress Bioscience, Inc.
![]() Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Algemeen Directeur | 01-12-1996 | 01-02-2011 |
Voorzitter | 01-12-1996 | 01-02-2011 | |
Cytel Corp. | Directeur/Bestuurslid | 01-01-1989 | 01-08-1995 |
Algemeen Directeur | 01-01-1989 | 01-08-1995 | |
President | 01-01-1989 | 01-08-1995 | |
Glytec Corp. | Algemeen Directeur | 01-01-1989 | 02-01-1990 |
Oprichter | 01-01-1989 | 01-01-1990 | |
President | - | 01-01-1990 | |
Perception Neuroscience, Inc.
![]() Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Algemeen Directeur | - | - |
Voorzitter | - | - | |
Oprichter | - | - | |
░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░ ░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░░ ░░ ░░░░░░░░░░ ░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Jay Kranzler
Yale University | Doctorate Degree |
Yeshiva University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 14 |
Canada | 2 |
Israël | 2 |
Operationeel
Chief Executive Officer | 7 |
Director/Board Member | 6 |
Chairman | 4 |
Sectoraal
Health Technology | 9 |
Consumer Services | 4 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
PFIZER, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 10 |
---|---|
Cypress Bioscience, Inc.
![]() Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Health Technology |
MSI Methylation Sciences, Inc.
![]() MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
Sequel Therapeutics, Inc.
![]() Sequel Therapeutics, Inc. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Sequel Therapeutics, Inc. is a company that develops immunotherapeutic vaccines. The company is based in San Diego, CA. The company was founded by Jay D. Kranzler. Sequel Therapeutics was acquired by Epimmune, Inc. from The Scripps Research Institute on October 18, 1995 for $6.90 million. | Health Technology |
Cytel Corp. | |
Glytec Corp. | |
Regenovation, Inc.
![]() Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | Commercial Services |
ImmunoBrain Checkpoint Ltd.
![]() ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
Perception Neuroscience, Inc.
![]() Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Health Services |
Pastorus, Inc.
![]() Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | Health Technology |
Baergic Bio, Inc.
![]() Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Health Technology |
- Beurs
- Insiders
- Jay Kranzler
- Ervaring